Combined administration of laminin-221 and prostacyclin agonist enhances endogenous cardiac repair in an acute infarct rat heart

Nagako Sougawa1, Shigeru Miyagawa1, Takuji Kawamura1, Ryohei Matsuura1, Akima Harada1, Yoshiki Sakai1, Noriko Mochizuki-Oda1, Ryoko Sato-Nishiuchi2, Kiyotoshi Sekiguchi2 & Yoshiki Sawa1

Although endogenous cardiac repair by recruitment of stem cells may serve as a therapeutic approach to healing a damaged heart, how to effectively enhance the migration of stem cells to the damaged heart is unclear. Here, we examined whether the combined administration of prostacyclin agonist (ONO1301), a multiple-cytokine inducer, and stem cell niche laminin-221 (LM221), enhances regeneration through endogenous cardiac repair. We administered ONO1301- and LM221-immersed sheets, LM221-immersed sheets, ONO1301-immersed sheets, and PBS-immersed sheets (control) to an acute infarction rat model. Four weeks later, cardiac function, histology, and cytokine expression were analysed. The combined administration of LM221 and ONO1301 upregulated angiogenic and chemotactic factors in the myocardium after 4 weeks and enhanced the accumulation of ILB4 positive cells, SMA positive cells, and platelet-derived growth factor receptor alpha (PDGFRα) and CD90 double-positive cells, leading to the generation of mature microvascular networks. Interstitial fibrosis reduced and functional recovery was prominent in LM221- and ONO1301-administrated hearts as compared with those in ONO1301-administrated or control hearts. LM221 and ONO1301 combination enhanced recruitment of PDGFRα and CD90 double-positive cells, maturation of vessels, and functional recovery in rat acute myocardial infarction hearts, highlighting a new promising acellular approach for the failed heart.

Abbreviations
AMI  Acute myocardial infarction
Ang1  Angiopoietin 1
ECM  Extracellular matrix
EF  Ejection fraction
FGF2  Fibroblast growth factor 2
FS  Fractional shortening
GAPDH  Glyceraldehyde-3-phosphate dehydrogenase
HGF  Hepatocyte growth factor
ILB4  Isolectin B4
IP  Prostaglandin I
LM  Laminin
LVIDd  Left ventricle internal dimensions at diastole
LVIDs  Left ventricle internal dimensions at systole
LVEDV  Left ventricular end-diastolic volume
LVESV  Left ventricular end-systolic volume

1Department of Cardiovascular Surgery, Osaka University Graduate School of Medicine, Suita, Osaka, Japan. 2Division of Matrixome Research and Application, Institute for Protein Research, Osaka University, Osaka, Japan. *email: sawa-p@surg1.med.osaka-u.ac.jp
Heart failure, including myocardial infarction, is often progressive and continues to be a major factor contributing to morbidity and mortality worldwide. Recently developed treatment strategies such as cell-based or drug therapy may potentially regenerate diseased heart tissue. However, the application of cell therapy is limited owing to the need for cell culture process, unsuitability with emergency use, and low versatility. Drugs that enhance the endogenous healing process may potentially regenerate the damaged heart tissue without the need for cell culture process and avoid the shortcomings associated with cell therapy. Therefore, induction of endogenous healing to enhance the recruitment of stem cells is thought as a promising approach to regenerate the damaged heart tissue. And also, how to effectively enhance the migration of stem cells to the damaged heart can be crucial for endogenous tissue repair.

ONO1301, a synthetic prostacyclin agonist with thromboxane A2 synthase inhibitory activity, has been shown to act as a multiple-cytokine inducer by ligating prostaglandin I (IP) receptors expressed on endothelial cells, vascular smooth muscle cells (vSMCs), or fibroblasts. Our laboratory demonstrated that administration of ONO1301 for acute and chronic ischemic cardiac failure animal models yielded proangiogenic cytokines, such as vascular endothelial growth factor (VEGF) or hepatocyte growth factor (HGF), and stromal cell-derived factor-1 (SDF-1), contributing to the repair of the tissues and inducing functional recovery.

The extracellular matrix (ECM) is essential for the structural support, maintenance, and differentiation of tissues and proposes a microenvironment that is suitable to support stem cell proliferation, migration, and fate decision. In particular, basement membranes contain structural proteins, including laminins, that are bound to the plasma membrane via specific receptors such as integrins. Laminin-221 (LM221) is the most likely expressed cardiac laminin that maintains physiological activities of myocytes. In addition, previously, we demonstrated that in rat acute myocardial infarction (AMI) model, administration of LM221 enhanced accumulation of smooth muscle actin (SMA) and isolectin B4 (ILB4) double-positive cells to the damaged area, and contributed to the improvement of cardiac function.

In this study, we hypothesized that the combined treatment with a prostacyclin agonist (ONO1301) and stem cell niche LM221 may enhance regeneration by mediating endogenous cardiac repair.

**Results**

**Combined administration of LM221 and ONO1301 enhanced cytokine expression.** We first analysed the expression of cytokines 4 weeks after treatment. We found that the expression of the cytokines related to angiogenesis and cell migration changed in the border area (Fig. 1). The relative gene expression levels of chemotactic factor such as SDF-1 was induced a significant elevation in LM221- and ONO1301-administration hearts compared to other groups (Control hearts; 1.00 ± 0.02, ONO1301-administrated hearts; 2.29 ± 0.11, LM221-administrated hearts; 1.81 ± 0.11, LM221- and ONO1301-administrated hearts; 3.29 ± 0.75, p < 0.05). In addition, combined administration of LM221 and ONO1301 in AMI model hearts led to increased gene expression of angiogenic factors such as HGF, placental growth factor (PIGF), angiopeitcin 1 (Ang1), fibroblast growth factor 2 (FGF2), Tie2, and platelet-derived growth factor beta (PDGF-B). The relative expression of PIGF was remarkably enhanced in LM221- and ONO1301-administrated hearts compared to control hearts and ONO1301-administrated hearts (Control hearts; 1.00 ± 0.06, ONO1301-administrated hearts; 1.49 ± 0.02, LM221- and ONO1301-administrated hearts; 2.09 ± 0.07, p < 0.05). However, there was no significant difference between LM221- and ONO1301-administrated hearts and LM221-administrated hearts. Although the relative expression of HGF was remarkably enhanced in LM221- and ONO1301-administrated hearts compared to control hearts and LM221-administrated hearts (Control hearts; 1.00 ± 0.02, LM221-administrated hearts; 1.81 ± 0.04, LM221- and ONO1301-administrated hearts; 3.30 ± 0.23, p < 0.05), there was no significant difference between LM221- and ONO1301-administrated hearts and ONO1301-administrated hearts. On the other hand, significant enhancement of gene expression of Ang1, FGF2, Tie2, and PDGF-B in LM221- and ONO1301-administrated hearts were observed only compared with control hearts.

The protein expression of these cytokines in LM221- and ONO1301-administrated hearts was also significantly higher than that in other hearts (Fig. 2). Four weeks after treatment, the number of SDF-1-positive cells in LM221- and ONO1301-administrated hearts were 4689.3 ± 662.1 cells/mm², which was significantly higher than that in control hearts (1453.3 ± 134.3 cells/mm², p < 0.05) (Fig. 2a), and, that of PIGF-positive cells in LM221- and ONO1301-administrated hearts was significantly higher than that in control hearts (160.5 ± 18.6 cells/mm², p < 0.05) (Fig. 2c). Similarly, the number of HGF-positive cells in LM221- and ONO1301-administrated hearts was 447.7 ± 27.7 cells/mm², which was significantly higher than that in control (91.0 ± 8.2 cells/mm², p < 0.05), ONO1301- (169.1 ± 31.6 cells/mm², p < 0.05), and LM221-administrated hearts (228.9 ± 22.5 cells/mm², p < 0.05). On the other hand, the number of Ang1-positive cells in LM221- and ONO1301-administrated hearts was not a significant elevation compared to other hearts (Fig. 2d).
Combined administration of LM221 and ONO1301 suppressed cell apoptosis. To examine the effects of administration on cell death, we analysed apoptotic factors. The relative expression levels of p53 gene in ONO1301-administrated, and LM221- and ONO1301-administrated hearts were 0.67 ± 0.06, and 0.71 ± 0.11, respectively, which were significantly lower than that in control hearts (\( p < 0.05 \)). On the other hand, the relative expression levels of Bcl2 gene in LM221- and ONO1301-administrated hearts was which was significantly higher than that in control hearts (\( p < 0.05 \)) (Fig. 3).

Combined administration of LM221 and ONO1301 promoted capillary maturation. Next, we investigated the nature of the cells that accumulated at the damaged site. Isolectin B4 (ILB4)-positive cells accumulated in the border area. The number of ILB4-positive cells in LM221- and ONO1301-administrated hearts (436.9 ± 20.8 cells/mm^2) was significantly higher than that in control hearts (226.3 ± 17.3 cells/mm^2, \( p < 0.05 \)) and ONO1301-administrated hearts (275.6 ± 26.4 cells/mm^2, \( p < 0.05 \)). However, those in LM221- and ONO1301-administrated hearts and LM221-administrated hearts (413.4 ± 5.4 cells/mm^2) was almost same (Fig. 4). On the other hand, the number of mature capillaries indicated with ILB4-positive vessels undercoated with SMA-positive cell in LM221- and ONO1301-administrated hearts (240.6 ± 15.5 cells/mm^2) tended to be higher than that in LM221-administrated hearts (153.8 ± 10.4 cells/mm^2/mm^2). In addition, the number of mature capillaries in LM221- and ONO1301-administrated hearts significantly increased compared to that in control hearts (57.9 ± 8.4 cells/mm^2, \( p < 0.05 \)) and ONO1301-administrated hearts (83.7 ± 0.7 cells/mm^2, \( p < 0.05 \)) (Fig. 5).

Combined administration of LM221 and ONO1301 increased PDGFRα and CD90 double-positive cell accumulation. The number of PDGFRα and CD90 double-positive cells in LM221- and ONO1301-administrated hearts (330.9 ± 32.2 cells/mm^2) was significantly higher than that in control hearts (160.8 ± 19.3 cells/mm^2, \( p < 0.05 \)) and LM221-administrated hearts (214.5 ± 37.5 cells/mm^2, \( p < 0.05 \)), however, that didn't show a significant increase compared to that in ONO1301-administrated hearts (251.5 ± 15.1 cells/mm^2) (Fig. 6).

Combined administration of LM221 and ONO1301 drove the infarct size suppression. The size of infarcted area in LM221- and ONO1301-administrated hearts (13.3% ± 2.0%) was significantly suppressed that of in control hearts (29.2% ± 3.2%, \( p < 0.05 \)) and in ONO1301-administrated hearts (23.7% ± 4.5%, \( p < 0.05 \)), while there was no significant difference between that of in LM221-administrated hearts (16.4% ± 0.4%) and LM221- and ONO1301-administrated hearts (Fig. 7).

Figure 1. Combined administration of LM221 and ONO1301 induced chemotactic cytokine and angiogenic cytokine gene expression. The expression of SDF-1, PIGF, HGF, Ang1, FGF2, TIE2, and PDGF-B in the infarcted area was measured by quantitative reverse-transcription polymerase chain reaction. Data were normalised to GAPDH expression. *\( p < 0.05 \).
Combined administration of LM221 and ONO1301 ameliorated the cardiac function. To assess the pathological effect, we evaluated the cardiac function in each group. As shown in Fig. 8a,b, control hearts showed a time-dependent decrease in the percentage of ejection fraction (EF) and fractional shortening (FS). ONO1301-administrated hearts and LM221-administrated hearts didn’t show much fluctuation in the percentage of EF and FS. However, the combined treatment with LM221 and ONO1301 displayed a time-dependent increase in the percentage of EF and FS. The relative EFs and FSs for LM221- and ONO1301-administrated hearts were significantly higher than that for control hearts 4 weeks after treatment (p < 0.05). However, there were no significant differences among LM221- and ONO1301-administrated hearts, LM221-administrated hearts, and ONO1301-administrated hearts (Fig. 8a,b). Although the left ventricle internal dimensions at diastole (LVIDd) in LM221- and ONO1301-administrated hearts was not a significant improvement, the left ventricle internal dimensions at systole (LVIDs) in the LM221- and ONO1301-administrated hearts was significantly improved compared to control hearts 4 weeks after treatment (Fig. 8c,d).
Discussion

Although cell-based therapy is a promising strategy for heart failure treatment, it is limited owing to the need for cell culture process, unsuitability with emergency use, and low versatility. To overcome these issues, we suggested a new acellular strategy in this study. Direct epicardial placement of LM221 and ONO1301 over the cardiac surface upregulated the expression of angiogenic and chemotactic factors in the myocardium at 4 weeks after transplantation. In addition, the combined administration of LM221 and ONO1301 suppressed cell death, and enhanced the accumulation of PDGFRα and CD90 double-positive cells or endothelial cells, leading to the generation of microvascular networks accompanied by SMA-positive cells. Lower fibrosis and effective functional recovery were shown in LM22-1 and ONO1301-administrated hearts than in ONO1301-administrated hearts, LM221 treated hearts and control hearts.

The vascular system is stabilized by the action of pericytes/SMCs, a process termed as maturation. Vascular maturation has been reported to be dependent on the members of the vascular endothelial growth factor (VEGF) family, FGF2, PDGF-B, and Ang1. The VEGF family or FGF2 play a critical role in the expression and recruitment of endothelial cells. PDGF-B secreted by endothelial cells controls mural cell recruitment to the endothelial cells. Ang1 produced by mural cells activates endothelial cells and maximizes their interaction with mural cells. These cytokine-related angiogenic processes produce a mature vascular system that avoids serious leakage and hemorrhage. ONO1301 activates endothelial cells, vascular smooth muscle cells and fibroblasts to release multiple cytokines. On the other hand, LM221 acts as a scaffold to store cells, growth factors and cytokines. In the present study, we confirmed the significant upregulation in the expression of chemotactic factors and angiogenic factors (SDF-1, HGF, FGF2, PIGF, PDGF-B, and Ang1) after treatment with the combination of LM221 and ONO1301, suggesting that this combined strategy enhances vascular maturation mediated by cytokine cocktails. Although the expression of VEGF was not significantly different among the groups (data...
not shown), that of PlGF, a member of the VEGF family, was significantly upregulated by the administration of ONO1301, and LM221 and ONO1301 compared to the control. Thus, PlGF may contribute to the sprouting of the vasculature instead of VEGF. In addition, HGF, FGF2, and PlGF, which were induced by the combined administration of LM221 and ONO1301, enhanced the proliferation and recruitment of ILB4-positive endothelial cells, while PDGF-B promoted vSMC migration to the vicinity of endothelial cells. Ang1 subsequently facilitated endothelial cell coverage via vSMCs\textsuperscript{16}. We speculate that vascular maturation in our model may be mediated by the mechanism described above.

The newly formed blood vessels through the action of a single cytokine may not have sufficient interaction with the surrounding vascular network and are not covered with mural cells. Vessels without mural cells demonstrate immature characteristics, leading to vascular leakage, hemorrhage, and early regression\textsuperscript{15}. In this study, the combined administration of LM221 and ONO1301 significantly increased the number of structurally mature vessels, as evident from ILB4-positive endothelial cells accompanied with SMA-positive cells as compared to the

Figure 5. Combined administration of LM221 and ONO1301 increased mature capillary density. Some ILB4-positive cells in the implanted site were coated with SMA-positive cells, as observed by immunohistochemical analysis. ILB4 and SMA double-positive cells increased following the combined administration of LM221 and ONO1301. Representative microscopic images show ILB4 (red), SMA (green), and nuclei (blue). Scale bar = 50 μm. The graph indicates the number of ILB4 and SMA double-positive cells at the implanted site. *p<0.05.

Figure 6. Combined administration of LM221 and ONO1301 increased PDGFRα and CD90 double-positive cell accumulation. PDGFRα and CD90 double-positive cells increased after the combined administration of LM221 and ONO1301, as observed by immunohistochemical analysis. Representative microscopic images show PDGFRα (red), CD90 (green), and nuclei (blue). Scale bar = 50 μm. The graph indicates the number of PDGFRα and CD90 double-positive cells at the implanted site. *p<0.05.
Figure 7. The combined administration of LM221 and ONO1301 reduced fibrosis. Fibrosis was observed by Picro-Sirius Red staining. (a) Representative microscopic images of the infarct size. Scale bars = 1000 μm. (b) The graph indicates the size of fibrosis at the implanted site 4 weeks after surgery. *p < 0.05.

Figure 8. The combined administration of LM221 and ONO1301 improved heart performance. (a,b) Line graphs depicting the left ventricle ejection fraction (EF, a) and fractional shortening (FS, b) 2 days and 2 and 4 weeks after treatment. (c,d) The statistical analysis of the echocardiographic results of the diastolic (LVIDd, c) and systolic (LVIDs, d) left ventricular internal diameter 4 weeks after treatment. *p < 0.05.
other groups. Thus, the combined strategy mediated effective angiogenesis for tissue repair. Although the origin of SMCs is not clearly elucidated in our experimental model, another cell type such as CD11b+ cells with c-kit expression or Sca-1+ cells having α7 integrin (a receptor for LM221) may have potentially differentiated into SMCs7,17. The accumulation of Sca-1+ cells at the border area was observed both in LM221-administrated and LM221- and ONO1301-administrated hearts (data not shown). And that made us speculate that the possibility of Sca-1+ cells differentiating into mural cells at the transplanted site.

The administration of LM221 alone was insufficient to accumulate PDGFRα and CD90 double-positive cells as compared with the combined treatment because these cells cannot be retained at the treatment site owing to the low expression of α7 integrin. These data suggest that SDF-1 induced by ONO1301 enhanced PDGFRα and CD90 double-positive cell recruitment into the transplanted site. In addition, the production of cytokines and the number of accumulated cells were higher in LM221- and ONO1301-administrated hearts than in the other hearts, suggesting the possibility that the cytokine expression was derived from endothelial cells activated by recruited cells.

Tissue homeostasis and wound repair are ensured by stem cells located within specialized microenvironments, referred to as niches. The stem cell niche comprises stem cells, neighboring cells, ECM, and secreted factors that are essential for cell survival and proliferation as well as to maintain the stability of undifferentiated stem cells18. The ECM is a scaffold for cells containing adhesion molecules such as integrins and is critical for the maintenance of the cytoskeleton as well as cell survival, growth, and fate19. LM221 is most abundantly expressed in the adult cardiac muscle and specifically binds to α7 integrin expressed in the myocardium9,20. LM221 is a scaffold for myocardiocytes and can influence cell maturation and survival through outside-in signaling21. These data suggest that the combined administration of LM221 and ONO1301 in vivo promotes stem cell differentiation, proliferation, and consequently improves cardiac function.

We proposed the following mechanisms in this paper. ONO1301 is linearly released and infiltrated into the cardiac tissue. IP receptor expressing cardiac cells, such as vascular smooth muscle cells, fibroblasts and endothelial cells, are activated by binding of ONO1301, leading to paracrine released cytokines, such as SDF-1, PIGF, or HGF. Cells, such as PDGFRα and CD90 double-positive cell, endothelial cell, or smooth muscle cell, are locally induced by SDF-1, and cells accumulate in the place using LM221 as a scaffold, leading to promotion of angiogenesis.

![Diagram](https://example.com/diagram.png)

**Figure 9.** Schematic figure of proposed mechanisms underlying LM221 and ONO1301-administrated treatment of myocardial infarction heart. ONO1301 is linearly released and infiltrated into the cardiac tissue. IP receptor expressing cardiac cells, such as vascular smooth muscle cells, fibroblast and endothelial cells, are activated by binding of ONO1301, leading to paracrine released cytokines, such as SDF-1, PIGF, or HGF. Cells, such as PDGFRα and CD90 double-positive cell, endothelial cell, or smooth muscle cell, are locally induced by SDF-1, and cells accumulate in the place using LM221 as a scaffold, leading to promotion of angiogenesis.

**Materials and methods**

**Animal care.** Animal care was performed as previously described11,22. The animal care procedures used in this study were reviewed and proved by the Guide for the Care and Use of Laboratory Animals (National Institutes of Health publication no. 85-23, revised 1996 no. 85-23, revised 1996). The experimental protocols were
approved by the Ethics Review Committee for Animal Experimentation of Osaka University Graduate School of Medicine (reference number 28-011-002) and adhered to the ARRIVE guidelines. All surgeries and sacrifices were performed under deep anesthesia with isoflurane sufficient to minimize animal suffering. All experiment procedures and evaluations were performed in a blinded manner.

**Recombinant LM.** Human LM221 was produced as a recombinant functionally active E8 fragment containing the collagen-binding domain of fibronectin at the N-terminus to facilitate binding to collagen sheets23–25. Recombinant LM221 was expressed using a FreeStyle 293 Expression System (Life Technologies, Carlsbad, CA, USA) and purified by sequential affinity chromatography using Ni–NTA agarose (Qiagen, Carlsbad, CA, USA) and anti-FLAG-M2-agarose (Sigma, St. Louis, MO, USA)16.

**Ligation of the left coronary artery and epicardial placement of collagen sheet in rats.** LM221 was resuspended in phosphate-buffered saline (PBS) at 100 nM concentration and applied to atelocollagen sheets (KOKEN, Tokyo, Japan) through immersion for 2 h at 37 °C. ONO1301 (Ono Pharmaceutical Co. Ltd., Osaka, Japan) was resuspended in saline and applied to atelocollagen sheets. Male athymic nude rats aged 6–8 weeks (F344 ’NJcl-rnu/rnu) were obtained from CLEA Japan (Tokyo, Japan). Left thoracotomy was performed under general anesthesia via the fourth intercostal space, and the branch of the left coronary artery was permanently ligated at the bottom of the left atrial appendage. Five minutes after ligation, LM221- and ONO1301-immersed atelocollagen sheets (KOKEN, Tokyo, Japan) (n = 8), LM221-immersed atelocollagen sheets (n = 10), ONO1301-immersed atelocollagen sheets (n = 10), or atelocollagen sheets (n = 11) were directly placed over the anterolateral surface of the left ventricle (LV) wall. After the approximation of the surgical wound, the rats were maintained in a temperature-controlled individual cage and then euthanized 4 weeks after the surgical procedure.

**Quantitative reverse transcription polymerase chain reaction (PCR).** Quantitative reverse transcription polymerase chain reactions were performed as previously described11. Total RNA was extracted from excised cardiac tissues and reverse transcribed using SuperScript III Reverse Transcriptase (Invitrogen) with random primers (Invitrogen). Quantitative PCR was performed using a Viia7 Real-Time PCR System (Applied Biosystems, Carlsbad, CA, USA) with rat-specific primers (Applied Biosystems) for Pdgf-B (Assay ID: Rn00585926_m1), Fgf2 (Assay ID: Rn00570809_m1), Hgf (Assay ID: Rn01775763_g1), and Sdf-1 (Assay ID: Rn01775763_g1). The specific primer sets for Ang1, Tie2, Pdgf-B, Caspase-3, P53, Bcl2 were as follows: Ang1, 5ʹagt cag gat ggc-3ʹ and 5ʹ-tgc aga aca atg ttg ttg ctg gc-3ʹ; Tie2, 5ʹ-cag gac ctt cac ccc aga acc ttc ttt cgc-3ʹ and 5ʹ-tcg tct aag aat gtc act aag ggt cca aag-3ʹ; Pdgf-B, 5ʹ-gct cct ttg ttt ttt aag ctt ccc ccc cgg cag cgc tgc acc tc-3ʹ and 5ʹ-ttc ctg ccc gag gag gcg aag acc atc tgt ttg ac-3ʹ; P53, 5ʹ-cac cag agg tgc aaa gag ag-3ʹ and 5ʹ-cag cgg aac atc tgt aag cag gc-3ʹ and 5ʹ-tgt ggt gat gac tga gta cct-3ʹ and 5ʹ-gag cag ggt ctg ctt cag ca-3ʹ; GpdpH, 5ʹ-ctc aag ggc tgt ggg caa ggt cat-3ʹ and 5ʹ-gag atc cac cac ctt ctt gct gtc gta-3ʹ. Each sample was analysed in triplicates for each gene. Data were normalised to GAPDH expression. For relative expression analysis, the delta-delta Ct method was used, and the values for the group treated with atelocollagen sheet only were used as reference.

**Histological analysis.** Histological analyses were performed as previously described11. The collected hearts were fixed with 4% paraformaldehyde (PFA) and embedded in optimal cutting temperature compound for sectioning. Frozen Sects. (5 μm) of transverse heart slices were incubated with antibodies against PDGFRα, CD90, SDF-1, HGF, PGF, Ang1 (Abcam, Cambridge, UK) and SMA (Dako, Glostrup, Denmark). Samples were then probed with Alexa Fluor 555- or 488-conjugated secondary antibodies (Invitrogen, Carlsbad, CA, USA). Results were confirmed with random primers (Invitrogen). Quantitative PCR was performed using a ViiA7 Real-Time PCR System from excised cardiac tissues and reverse transcribed using SuperScript III Reverse Transcriptase (Invitrogen) and purified by sequential affinity chromatography using Ni–NTA agarose (Qiagen, Carlsbad, CA, USA) and anti-FLAG-M2-agarose (Sigma, St. Louis, MO, USA).16.

**Statistical analysis.** Data are expressed as mean ± standard error of the mean. Data distributions were checked for normality. Multiple comparisons were assessed using one-way analysis of variance (ANOVA) with Tukey–Kramer post-hoc testing. All p values were two-sided, and values of p < 0.05 were considered statistically significant.
Received: 4 December 2020; Accepted: 27 September 2021
Published online: 15 November 2021

References

1. Conrad, N. et al. Temporal trends and patterns in heart failure incidence: a population-based study of 4 million individuals. The Lancet 391, 572–580 (2018).
2. Koitabashi, N. & Kass, D. A. Reverse remodeling in heart failure: mechanisms and therapeutic opportunities. Nat. Rev. Cardiol. 9, 147–157 (2012).
3. Fukushima, S., Miyagawa, S., Sakai, Y. & Sawa, Y. A sustained-release drug-delivery system of synthetic prostacyclin agonist, ONO-1301SR: a new reagent to enhance cardiac tissue salvage and/or regeneration in the damaged heart. Heart Fail. Rev. 20, 401–413 (2015).

Acknowledgements

We thank Kaori Ikuma for their excellent technical assistance.

Author contributions

N.S. participated in research design, performance of experiments, data analysis, and writing of the article. S.M. participated in research design, data analysis, and writing of the article. T.K. and R.M. provided critical advice and participated in writing of the article. A.H. participated in the research, data analysis, and writing of the article. T.K., R.M. and N.O. provided critical advice and helped to write the article. Y.S., R.N. and K.S. contributed reagents and provided critical advice. Y.S. directed this research and reviewed the article.

Funding

This study was supported in part by the New Energy and Industrial Technology Development Organization.

Competing interests

The authors declare no competing interests.

Additional information

Correspondence and requests for materials should be addressed to Y.S.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
